

7/11/2011; Page 1

Suggested Formula

Progesterone 75 mg Oral Tablets (Solid Suspension, 100 Tablets)

FIN F 003 766v2

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Progesterone (Micronized), USP	7.500	g				
Lactose (Monohydrate), NF	TBD					
Methylcellulose (1500 CPS), USP	TBD					
Gelatin, NF	TBD					
Stevia Powder	TBD		0			
Tutti Frutti Flavor	TBD					
Water-Alcohol 1:3 mixture †	As required		C X			
† Water-Alcohol 1:3 mixture			\mathbf{D}_{1}			
Purified Water, USP	10.0	mL				
Alcohol (95%), USP	30.0	mL				
	/					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible):

Methylcellulose (1500 CPS), Stevia Powder

preparation, it is suggested to

Light sensitive (protect from light whenever possible):

Progesterone

Suggested Preparatory Guidelines

Non-Sterile Preparat	ion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing error considerations during preparation, it is suggest measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



7/11/2011; Page 2 TMP 023

Suggested
FormulaProgesterone 75 mg Oral Tablets (Solid Suspension, 100 Tablets)FINF 003 766v2

SUGGESTED PREPARATION (for 100 Tablets)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Progesterone (Micronized), USP §	7.500	g			
Lactose (Monohydrate), NF	TBD				
Methylcellulose (1500 CPS), USP §	TBD				
Gelatin, NF	TBD		8		
Stevia Powder §	TBD				
Tutti Frutti Flavor	TBD				
Water-Alcohol 1:3 mixture †	As required	5			
			1		
† Water-Alcohol 1:3 mixture					
Purified Water, USP	10.0	mL			
Alcohol (95%), USP	30.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

ual size of the tablet mold



7/11/2011; Page 3

	aggested FormulaProgesterone 75 mg Oral Tablets (Solid Suspension, 100 Tablets)FINF 003 766v2							
3.	Powder preparation:							
	A. Combine and mix the following ingredients together to form a homogeneous powder blend:							
	 Lactose (Monohydrate) (amount calculated in Appendix Step 8) Methylcellulose (1500 CPS) (amount calculated in Appendix Step 8) Gelatin (amount calculated in Appendix Step 8) Stevia Powder (amount calculated in Appendix Step 8) Tutti Frutti Flavor (amount calculated in Appendix Step 8) 							
	B. By geometric addition, combine and mix the following ingredients together to form a homogeneous powder blend:							
	 Progesterone (Micronized) Homogeneous powder blend (Step 3A) 							
4.	Phase integration:							
	A. Incrementally add the Water-Alcohol 1:3 mixture (Step 2A) to the homogeneous powder blend (Step 3B) and mix until homogeneously dispersed.							
	Specification: Continuously mix.							
	End results: Homogeneous paste-like dispersion.							
	IMPORTANT: Add the Water-Alcohol mixture, a few drops at a time and mix well until the mixture attains a paste-like consistency. Do not add too much.							
5.	Mold filling:							
	A. Fill each of the 100 tablet mold with the API-excipient mixture (Step 4A), and press into the molds until firmly packed and uniform.							
	B. Allow the tablets to air dry then gently remove them from the mold.							
6.	Validation technique:							
	A. Weigh 20 tablets separately.							
	 B. The final weight of each tablet from Step 6A (not including the weight of the tablet mold) should be between 90 and 110% of the theoretically calculated weight (Appendix, Step 6B), in accordance to USP guidelines. 							
7.	Product transfer:							
	Transfer the final product into the specified dispensing container (see "Packaging Requirements").							
	•							



7/11/2011; Page 4 TMP 023

Suggested Formula

Progesterone 75 mg Oral Tablets (Solid Suspension, 100 Tablets)

FIN F 003 766v2

SUGGESTED PRESENTATION

В	Estimated Beyond-Use Date		6 months, as per USP	Packagi Requiremen		Tight, light-resistant vials.	
		1	Use as directed. Do not exceed dose.	l prescribed	6	Protect from light.	
		2	Keep out of reach of children.			Keep in a dry place.	
	A 11	3	Keep at room temperature ($20^{\circ}C - 23^{\circ}C$).			Cap tightly after use.	
	Auxiliary Labels	4	4 May impair mental and/or physical ability. Use care when operating a car or machinery.		9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	
		5	Consult your health care practit prescription or over medications are currently being prescribed for future use.	-the-counter			
	Pharmacist Instructions Add any auxiliary labels specific to the API to the			he API to the	disp	ensing container as deemed necessary.	
	Patient Instructions	If a	allergic reactions occur, consult yo	our pharmacis	t.		



7/11/2011; Page 5 TMP 023

Suggested Formula

Progesterone 75 mg Oral Tablets (Solid Suspension, 100 Tablets)

FIN F 003 766v2

REFERENCES

1.	Tablets. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 145.
2.	Crinone. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2008. 607.
3.	Lactose, monohydrate. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 5 th Edition. American Pharmaceutical Association; 2006: 389.
4.	Gelatin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 5 th Edition. American Pharmaceutical Association; 2006: 295.
5.	Methylcellulose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 5th Edition</i> . American Pharmaceutical Association; 2006: 462.
6.	Progesterone. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 2125.
7.	Progesterone (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #7773.
8.	Progesterone. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations,4th Edition</i> . American Pharmaceutical Association; 2009: 473.
9.	Progesterone (Monograph). United States Pharmacopeia XXXI / National Formulary 26. Rockville, MD. US Pharmacopeial Convention, Inc. 2008.
10.	Progesterone. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2526.
11.	USP <795>. United States Pharmacopeia XXXI / National Formulary 26. Rockville, MD. US Pharmacopeial Convention, Inc. 2008.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



7/11/2011; page 1

Appendix Tablet mold calibration

SUGGESTED CALCULATION

Preparatory Instruction

1. API weighing:

A. Weigh and / or measure the following ingredients:

Ingredient	Quantity	
Progesterone (Micronized), USP	0.750 g	
Lactose (Monohydrate), NF	1.67 g	8
Methylcellulose (1500 CPS), USP	0.045 g	
Gelatin, NF	0.49 g	
Stevia Powder	0.002 g	
Tutti Frutti Flavor	0.02 g	1
Water-Alcohol 1:3 mixture †	As required	
† Water-Alcohol 1:3 mixture	×	
Purified Water, USP	1.0 mL	
Alcohol (95%), USP	3.0 mL	

Notes: - Weigh the exact amount, do not consider processing error for calibration step. - Data within this calibration table are based on a 0.2 mL mold size.

2. † Water – Alcohol 1:3 mixture preparation:

A. Combine and mix the following ingredients together until homogeneously dispersed:

- Purified Water - 1.0 mL

- Alcohol (95%) – 3.0 mL

End result: Homogeneous liquid-like solution.



7/11/2011; page 2

Ap	ppendix Tablet mold calibration							
3.	Powder-liquid preparation:							
	A. Combine and mix the following ingredients together to form a homogeneous powder blend:							
	- Lactose (Monohydrate) Methyleollulose (1500 CPS)							
	- Methylcellulose (1500 CPS) - Gelatin							
	- Stevia Powder - Tutti Frutti Flavor							
	B. By geometric addition, combine and mix the following ingredients together to form a homogeneous Powder blend:							
	- Progesterone (Micronized)							
	- Homogeneous powder blend (Step 3A)							
4.	Phase integration:							
	A. Incrementally add the Water-Alcohol 1:3 mixture (Step 2A) to the homogeneous powder blend (Ste	ep 3B) and mix						
	until homogeneously dispersed.	1 -)						
	Specification: Continuously mix.							
	End results: Homogeneous paste-like dispersion.							
	IMPORTANT: Add the Water-Alcohol mixture, a few drops at a time and mix well until the m paste-like consistency. Do not add too much.	ixture attains a						
5.	Mold filling:							
	A. Fill 5 tablet molds with the mixture (Step 4A), and press into the molds until firmly packed and unif	orm.						
	B. Allow the tablets to air dry and remove them from the mold.							
6.	Calculate the average tablet weight:							
	A. Weigh the five tablets and record the total weight here (not including the weight of the empty tablet mold):							
	B. Calculate the average tablet weight:							
	Combined weight of the tablets (from Step 6a): g DIVIDED BY							
	Number of Tablets 5							
	EQUALS							
	Average (theoretical) tablet weightg							



7/11/2011; page 3

А	ppendix	Tablet mol	d calibration							
7.	 7. Ingredient calculation: A. Calculate the quantity of excipient blend required for 100 tablets: 									
	Average tablet weight (from Step 6B) MINUS								g	
		Quantity (in g) of Progesterone (Micronized) per tablet							0.075 g	
			tity of excipi	ent blend 1	required per t	ablet			g	
			of tablets rec	quired		6		Ċ.	100	
		EQUALS		excipient l	olend required	l for 100	tablets	Υ	g	
8.	Calcula	ate the req	uired quant	ities of eac	h individual e	xcipient	for 100 Tabl	ets:		
	Ing	gredient	Proportion		Quantity of Excipient blend required (Step 7Aii)		Quantity of each individual Excipient required		Processing error	Quantity of each individual Excipient required plus processing error
	Lacto	ose	0.75203							g
	Methy	ylcellulose	0.02033							g
	Gelati	in	0.22019	Multiply	g	Equals		Multiply	1.05 - 1.09	g
	Stevia	a Powder	0.00068							g
	Tutti I	Frutti	0.00678							g

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.